Accuracy of wavefront aberrometry in cataract patients

Article

Loss of optical media transperency reduces accuracy in clinical practice

Wavefront aberrometry (WA) offers promising applications in ophthalmology and can provide valuable information in previously underresearched conditions including hyperopia and cataract-related reduced visual acuity (VA). In clinical settings, WA is frequently used to assess patients presenting for refractive surgery, and previous studies have demonstrated a high level of accuracy of WA measurements in comparison to those of manifest refraction (MR) and autorefraction. However, the subjects of these studies have primarily been young, myopic and well-sighted patients, while in clinical practice the majority of patients presenting for cataract surgery are of advanced age, with ametropia and reduced VA.

As a patient's VA can be affected when WA is used as a basis for surgical treatment of pathological conditions (particularly if the measurements are less accurate in specific patient populations), Dr Stephan Linke, Dr Jan Hülle (University Medical Center HamburgEppendorf, Germany) and colleagues decided to conduct a study to evaluate the accuracy of WA in comparison to MR in an older population awaiting cataract surgery.1 The trial was intended to help the team determine if previous study results can be replicated in clinical practice and to establish which factors, if any, affect the accuracy of the refractive values as measured by WA.

Assessing the eyes

"We had anticipated that WA would measure the same refractive values as MR, but that potential measurement differences between the devices would be explained either by the refractive state - hyperopia versus myopia - or by age. We also thought that the only impact of cataract on the results would be that more progressed forms of cataract would lead to more exaggerated differences between measurements taken on the separate devices," explained Dr Hülle. "However, some of the results we actually achieved were surprising, and were in fact contrary to previously published conclusions."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.